Skip to website navigation Skip to article navigation Skip to content

A page refresh occures when a subject is selected.

Skip article navigation.

Innovating for patients with severe diseases

Where we innovate

Where we innovate

We have world class discovery, research and development facilities, and re-invest more than a quarter of our revenue in research and development (R&D) activities around the world.

  • Our Braine-l’Alleud Research Campus, based just outside Brussels in Belgium, is the hub for UCB’s manufacturing, research and development expertise, particularly with regards to biologic and solutions for neurological diseases.

  • Our Slough facility in the U.K. focuses on research and development for immunology therapies.

  • In 2020, we acquired a new campus in Windlesham, Surrey for UCB’s U.K. operations. Once operational in 2024, this site will support cutting-edge research and development, early manufacturing and commercialization of medicines. This reflects UCB’s commitment to retain the U.K. as one of its three global hubs for research, alongside Belgium and the U.S, in spite of the U.K.’s departure from the European Union.

  • In the U.S., UCB’s Boston R&D Hub , established in 2017, now has more than 125 people driving our work in areas including targeted protein degradation, protein biochemistry, and structural biology to help us discover new medicines for treating patient populations with severe neurodegenerative and immunological diseases.